IL308222A - Combination therapies that include SHP2 inhibitors and PD-1 inhibitors - Google Patents

Combination therapies that include SHP2 inhibitors and PD-1 inhibitors

Info

Publication number
IL308222A
IL308222A IL308222A IL30822223A IL308222A IL 308222 A IL308222 A IL 308222A IL 308222 A IL308222 A IL 308222A IL 30822223 A IL30822223 A IL 30822223A IL 308222 A IL308222 A IL 308222A
Authority
IL
Israel
Prior art keywords
inhibitors
combination therapies
shp2
shp2 inhibitors
therapies
Prior art date
Application number
IL308222A
Other languages
English (en)
Hebrew (he)
Inventor
Farbod Shojaei
Jill M Ricono
Robert Goodenow
Mireille Gillings
Original Assignee
Huyabio Int Llc
Farbod Shojaei
Jill M Ricono
Robert Goodenow
Mireille Gillings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huyabio Int Llc, Farbod Shojaei, Jill M Ricono, Robert Goodenow, Mireille Gillings filed Critical Huyabio Int Llc
Publication of IL308222A publication Critical patent/IL308222A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL308222A 2021-05-05 2022-05-04 Combination therapies that include SHP2 inhibitors and PD-1 inhibitors IL308222A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163184685P 2021-05-05 2021-05-05
US202263320997P 2022-03-17 2022-03-17
PCT/US2022/027696 WO2022235817A1 (en) 2021-05-05 2022-05-04 Combination therapies comprising shp2 inhibitors and pd-1 inhibitors

Publications (1)

Publication Number Publication Date
IL308222A true IL308222A (en) 2024-01-01

Family

ID=83932910

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308222A IL308222A (en) 2021-05-05 2022-05-04 Combination therapies that include SHP2 inhibitors and PD-1 inhibitors

Country Status (8)

Country Link
US (1) US12097203B2 (enExample)
EP (1) EP4334318A4 (enExample)
JP (1) JP2024516037A (enExample)
AU (1) AU2022271243A1 (enExample)
CA (1) CA3217084A1 (enExample)
IL (1) IL308222A (enExample)
MX (1) MX2023013064A (enExample)
WO (1) WO2022235817A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023012929A (es) * 2021-05-05 2023-11-13 Huyabio Int Llc Terapias de combinacion que comprenden inhibidores de shp2 e inhibidores de tirosina cinasa egfr.
CN121013721A (zh) * 2022-11-23 2025-11-25 沪亚生物国际有限公司 包含kras抑制剂和sph2抑制剂的组合疗法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
WO2015107494A1 (en) 2014-01-17 2015-07-23 Novartis Ag 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
WO2016203406A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
WO2017210134A1 (en) 2016-05-31 2017-12-07 Board Of Regents, University Of Texas System Heterocyclic inhibitors of ptpn11
KR102218333B1 (ko) 2016-06-07 2021-02-22 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
PT3468972T (pt) * 2016-06-14 2020-08-21 Novartis Ag Compostos e composições para inibir a atividade da shp2
IL311645B2 (en) 2016-07-12 2025-11-01 Revolution Medicines Inc 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors
CN110730678B (zh) 2017-01-10 2022-07-15 诺华股份有限公司 包含alk抑制剂和shp2抑制剂的药物组合
SG11201908820VA (en) 2017-03-23 2019-10-30 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
TWI852912B (zh) 2017-09-07 2024-08-21 美商銳新醫藥公司 Shp2抑制劑組合物以及治療癌症的方法
BR112020007058A2 (pt) 2017-10-12 2020-10-06 Revolution Medicines, Inc. compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos
WO2019126736A1 (en) 2017-12-21 2019-06-27 New York University Pd-1 related cancer therapy
WO2019152454A1 (en) 2018-01-30 2019-08-08 Research Development Foundation Shp2 inhibitors and methods of use thereof
RU2020133727A (ru) 2018-03-21 2022-04-21 Сучжоу Пухе Биофарма Ко., Лтд. Ингибиторы shp2 и их применение
KR20200143417A (ko) 2018-04-10 2020-12-23 레볼루션 메디슨즈, 인크. Shp2 억제제 조성물, 암을 치료하는 방법 및 shp2 돌연변이를 갖는 대상체를 확인하는 방법
JP2022508651A (ja) * 2018-10-08 2022-01-19 レヴォリューション・メディスンズ，インコーポレイテッド 癌を処置するためのｓｈｐ２阻害剤組成物および方法
EP3923940B1 (en) 2019-02-12 2025-12-03 Novartis AG Pharmaceutical combination comprising tno155 and a pd-1 inhibitor
CN111647000B (zh) * 2019-03-04 2021-10-12 勤浩医药（苏州）有限公司 吡嗪类衍生物及其在抑制shp2中的应用
CN114502165A (zh) 2019-09-23 2022-05-13 苏州浦合医药科技有限公司 Shp2抑制剂及其用途

Also Published As

Publication number Publication date
MX2023013064A (es) 2023-11-15
US12097203B2 (en) 2024-09-24
AU2022271243A1 (en) 2023-11-30
WO2022235817A1 (en) 2022-11-10
EP4334318A4 (en) 2025-03-05
US20220370457A1 (en) 2022-11-24
CA3217084A1 (en) 2022-11-10
EP4334318A1 (en) 2024-03-13
JP2024516037A (ja) 2024-04-11

Similar Documents

Publication Publication Date Title
SG11202111262XA (en) Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
IL291285B1 (en) Inhibitors of shp2 phosphatases and methods for their preparation and use
IL277434B1 (en) shp2 phosphatase inhibitors and methods of using them
PT3911648T (pt) 6¿-[[(1s,3s)-3-[[5-(difluorometoxi)-2-pirimidinil]amino]ciclopentil]amino][1(2h),3¿-bipiridina]-2-ona como inibidor de pcsk9 e seus métodos de utilização
IL297625B2 (en) PI3K-alpha inhibitors and methods of using them
IL287973A (en) acss2 inhibitors and methods of their use
IL312348A (en) HIF-2ALPHA inhibitors and methods of using it
IL285927A (en) Combinations of rad51 and parp inhibitors
EP3986894A4 (en) ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF
IL264854A (en) Spt5 inhibitors and methods of use thereof
IL289127A (en) ppm1a inhibitors and methods of using them
IL277918A (en) A combination of LIF inhibitors and PD-1 AXIS inhibitors for use in cancer therapy
IL326819A (en) Complement factor b inhibitors and uses thereof
IL308868A (en) Combined treatments with SETD2 inhibitors
EP3959197A4 (en) PAPD5 INHIBITORS AND METHODS OF USE THEREOF
GB202214644D0 (en) Sars-cov-2 mpro inhibitors and uses thereof
EP4334318A4 (en) COMBINATION THERAPIES WITH SHP2 INHIBITORS AND PD-1 INHIBITORS
IL291396A (en) mll1 inhibitors and anticancer drugs
IL321255A (en) ADAR1 inhibitors and methods of using them
IL286149A (en) Caspase inhibitors and methods of using them
ZA202105833B (en) Arginase inhibitors and methods of use thereof
WO2021067572A3 (en) Compositions and methods for inhibiting carp-1 binding to nemo
CA3273568A1 (en) Combination therapies comprising kras inhibitors and sph2 inhibitors
HK40060839A (en) Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
HK40047083A (en) Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer